An underground economy for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on new investigations.
Investigational Drug Gaining Traction Online
The experimental drug, which remains in research studies, is being promoted by online personalities for its alleged fat-burning effects. Followers are encouraged to message these accounts privately for supplier links, while also obtaining promotional offers.
Active Trade on Messaging Platforms
Separately, a flourishing market exists on messaging services, where groups with thousands of members share comparison photos, administration instructions and claims of next-day UK delivery. Vendors promote the substance there before directing buyers to other platforms for purchases.
Learning About Retatrutide
Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could help patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed online as the successor to Ozempic.
Medical Experts Voice Concerns
However, doctors and pharmacists have cautions that the sale of what remains an unapproved drug in the UK is a cause for concern and could result in individuals administering products of unknown origin.
Some experts stated the demand for the experimental drug could be connected to the increasing cost of licensed slimming products such as Mounjaro.
Regulatory Position and Implementation
Selling retatrutide on social media or Telegram is illegal in the UK, as it is an unlicensed medication that must not be promoted or distributed for human use under the British medical regulations.
Some influencers attempt to sidestep the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still breach pharmaceutical, marketing, and customer regulations, potentially leading to fines, legal action or imprisonment.
Platform Response and Content Removal
Based on TikTok, the service has removed problematic material and prohibited associated keywords and query recommendations. The company stated it was dedicated to keeping the service secure and allocating resources in enhancing enforcement strategies.
Digital Marketplace Operations
Research also discovered groups with up to nine thousand members selling the experimental drug using the platform's built-in discovery tool, which functions like a online catalog. Entering “retatrutide” immediately displays groups with numerous of users, populated with photos of weight loss, positive reviews and detailed instructions for mixing or injecting at home.
Within minutes of joining one community, a vendor shared WhatsApp details, where the majority of transactions occur. The seller sent an guidebook and promised delivery within 48 hours. When questioned whether the product was genuine, one seller said: “You can’t be sure.” Another provided a image of a alleged testing documentation. None asked about body mass, medical conditions or past usage.
Item Information and Pricing
Within these groups, posts display dark colored parcels with postal service stickers, stating to include fresh supplies. One message stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, prepared at home with purified liquid, or ready-to-use injectors usually priced at 160 pounds for 20 milligrams. When asked how much time a pen should be used, sellers give conflicting answers ranging from a few weeks to “depends on your body”.
Service Moderation and Safety Measures
A representative for Telegram stated it actively moderated dangerous content on its service including content that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“Individuals are administering materials they cannot confirm. Even if the research behind this drug is sound, these digital versions may not include what they advertise,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.
A medical professional of an online medical service connected the surge in interest to recent cost increases for approved weight-loss medications such as Mounjaro. “With costs rising, individuals are using social media. But fake injections are extremely dangerous. You cannot know what’s contained or whether the conditions they were produced in was clean,” she explained.
Her staff has previously seen patients injured by personal administration from unverified sources. “We recognize the frustration, but buying from messaging apps or WhatsApp is gambling with your health,” said the doctor. “These materials could be impure or incorrectly dosed.”
Manufacturer Position
A representative from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any government authority globally. “Therefore at this time no one can market [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a company experimental substance not yet authorized … may expose patients to potentially significant health risks”.
